Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
51.7M
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
28M
-
Shares change
-
+26.1M
-
Total reported value, excl. options
-
$56.3M
-
Value change
-
+$52.5M
-
Number of buys
-
22
-
Number of sells
-
-6
-
Price
-
$2.01
Significant Holders of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) as of Q3 2025
38 filings reported holding SABS - SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q3 2025.
SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28M shares
of 51.7M outstanding shares and own 54.18% of the company stock.
Largest 10 shareholders include Vivo Capital, LLC (11.4M shares), Commodore Capital LP (4.4M shares), RA CAPITAL MANAGEMENT, L.P. (4.4M shares), Woodline Partners LP (2.85M shares), Sessa Capital IM, L.P. (2.2M shares), BVF INC/IL (933K shares), SPHERA FUNDS MANAGEMENT LTD. (566K shares), VANGUARD GROUP INC (366K shares), HB Wealth Management, LLC (308K shares), and AWM Investment Company, Inc. (200K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.